SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.50-1.3%Jan 16 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (6474)6/4/2002 5:38:46 PM
From: Ian@SI  Read Replies (3) of 52153
 
Edited to add RS opinion. 5:50PM Tuesday

If we can believe Briefing.Com, they also seem to think that MLNM is cheap at current prices. It would also appear that the stock is just entering that zone (2 years before and after first Q of profitability) where investors stand to make the largest profit.

FWIW,
Ian
++++++++++++++++++++++

10:02 ET Millennium Pharm sees Integrilin growth of 30%, profitability in 2 years (MLNM) 13.05 -0.58: -- Update -- Hearing from a source listening to MLNM's presentation at the Needham Biotech conference that the co expects Integrilin sales to grow 30% annually for the next 3 years (we're told the previous expectation was for 25% sales growth), and expects to bring 1-2 products to mkt per year and 3-4 products per year to the clinic by 2005. In addition, co says they will have $1.7 bln in cash by year-end, and expects to be profitable in 2 years (current consensus sees losses through 2003-04).

++++++++++++++

14:33 ET Millennium Pharm: positive comments by Robbie (MLNM) 13.32 -0.31: -- Update -- Robertson Stephens says MLNM is the most compelling stock in their coverage universe, and sees a significant flow of potentially positive catalysts for the remainder of the year, including Phase II data on MLN-09 and MLN-02 in August, CRUSADE data at AHA in Nov, and final Phase II data on MLN-341 in multiple myeloma at ASH in Dec; firm also notes that the co trades for $3.2 bln yet has $2 bln in cash.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News